CardioCel studies presented at medical conferences

Allied Healthcare’s (ASX:AHZ) findings from recent studies into using its CardioCel tissue patch in heart valve repair and stem cell growth were recently presented at two key medical conferences.

The studies were the subject of two peer-review presentations at last week’s American Association of Thoracic Surgeons (AATS) mitral conclave meeting and last month’s Society for Biomaterials meeting.

Melbourne professor Christian Brizard presented data from the CardioCel heart valve reconstruction study at the AATS meeting in New York.

The results show that CardioCel was able to regenerate native heart valve tissue while helping to preserve valvular function over time - without the calcification problem common to heart valve reconstruction.

“The presentation last week to a full auditorium of leading heart surgeons in the US highlighted the significant unmet need CardioCel can provide in the future treatment of heart defects that require tissue repair and reconstruction including repairing heart valves,” said Allied Healthcare Group Managing Director Lee Rodne.

CSIRO scientists last month also used the Society for Biomaterials meeting to present details from their joint study with Allied Healthcare involving the use of CardioCel for stem cell seeding.

Allied Healthcare and the CSIRO commenced their stem cell research collaboration in July last year.

Allied Healthcare shares were trading 3.45% higher at $0.03 as of around 1 pm on Monday.